Stockscreener 앱 받기
33.92
6.40%
2.04
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Published on: 2026-01-18 12:53:17 - baoquankhu1.vn
Viking Therapeutics Stock (VKTX) Opinions on VK2735 Obesity Drug Results - Quiver Quantitative
Volume Summary: What is AEISs valuation compared to sector2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Viking Therapeutics: A Stock at a Crossroads Amid Obesity Drug Ambitions - AD HOC NEWS
Is Viking Therapeutics (VKTX) Now Attractive After A Strong DCF Upside Signal - Yahoo Finance
Viking Therapeutics Stock Navigates a Week of High Volatility - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
The Escalator: AstraZeneca, Viking Therapeutics, VML Health and more - Medical Marketing and Media
M&A Speculation Fuels Rally in Viking Therapeutics Shares - AD HOC NEWS
Why Viking Therapeutics (VKTX) Is Up 6.1% After VK2735 Phase 2 Obesity Data And Phase 3 Progress - simplywall.st
Viking Therapeutics (VKTX) Soars 11.9% on Strong Weight Loss Market Outlook - Insider Monkey
VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals - Stocktwits
Viking Therapeutics Unveils Promising Phase 2 Clinical Success, Fuels Stock Surge - timothysykes.com
Precision Trading with Viking Therapeutics Inc. (VKTX) Risk Zones - Stock Traders Daily
Viking Therapeutics (NASDAQ:VKTX) Trading 8.3% HigherShould You Buy? - MarketBeat
$VKTX stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals - TechStock²
Stocks Drop, Energy Sector Rises As Crude Eyes 6th Day Of Gains: What's Moving Markets Wednesday? - Benzinga
SG Americas Securities LLC Acquires 81,519 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics: Positioning in the Competitive Obesity Drug Arena - AD HOC NEWS
Jim Cramer Says "I'm a Eli Lilly Guy" When Asked About Viking Therapeutics - Finviz
Jim Cramer Says “I’m a Eli Lilly Guy” When Asked About Viking Therapeutics - Insider Monkey
Viking Therapeutics Gains Investor Attention with Key Clinical Data and Strategic Positioning - AD HOC NEWS
Dow Update: Why Viking Therapeutics Inc. stock remains undervaluedMarket Risk Summary & AI Powered Market Entry Ideas - moha.gov.vn
Assessing Viking Therapeutics (VKTX) Valuation After Positive VK2735 Obesity Trial Progress - simplywall.st
Viking Therapeutics Bolstered by Clinical Data and Development Momentum - AD HOC NEWS
Appetite for weight-loss deals broader than visible, Viking CEO says - Reuters
Viking Therapeutics Gains Scientific Endorsement for Weight Loss Candidate - AD HOC NEWS
Profit Recap: Why is Viking Therapeutics Inc stock going upPrice Action & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Viking Therapeutics announces publication of results from Phase 2 VENTURE trial - TipRanks
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity - PR Newswire
Viking Therapeutics Sharpens Commercial Focus for Obesity Drug Pipeline - AD HOC NEWS
What Investors Should Know About a Viking Therapeutics Insider's $2 Million Stock Sale - AOL.com
1 bold prediction for Viking Therapeutics in 2026 - MSN
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise - MSN
Is Viking Therapeutics (VKTX) Quietly Recasting Its Metabolic Ambitions With VK2735 And New Leadership? - Yahoo Finance
Viking Therapeutics: A High-Stakes Bet on Clinical Success - AD HOC NEWS
Viking Therapeutics stock suffers worst day in over 4 months as top execs dump shares — Novo’s $149 Wegovy move looms - MSN
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know - sharewise.com
Why Viking Therapeutics Inc. stock remains on buy listsTrade Volume Summary & Daily Oversold Bounce Ideas - ulpravda.ru
Has The Pullback In Viking Therapeutics (VKTX) Opened A New Valuation Opportunity - simplywall.st
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug - Yahoo Finance
Viking Therapeutics Stock Faces Pressure Amid Insider Sales - AD HOC NEWS
Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Viking Therapeutics completes enrollment in obesity drug maintenance study By Investing.com - Investing.com Nigeria
Viking Therapeutics completes enrollment in trial of VK2735 - Yahoo Finance
Viking Therapeutics Advances Obesity Drug Development and Commercial Strategy - AD HOC NEWS
Will Viking Therapeutics’ New CCO Reframe VKTX’s Obesity Strategy Amid Intensifying GLP-1 Competition? - Sahm
Can Viking Therapeutics Inc. stock maintain growth trajectoryJuly 2025 Snapshot & Real-Time Volume Trigger Notifications - ulpravda.ru
Viking Therapeutics: InvestingPro’s overvalued call proved right amid volatility By Investing.com - Investing.com Nigeria
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - Finviz
Brokers suggest investing in Viking Therapeutics (VKTX): Read this before placing a bet - MSN
How Viking Therapeutics Inc. stock performs during Fed tightening cyclesPortfolio Performance Summary & Free Daily Entry Point Trade Alerts - ulpravda.ru
Will Viking Therapeutics Inc. stock outperform growth indexes2025 Fundamental Recap & Low Drawdown Momentum Ideas - ulpravda.ru
Viking Therapeutics (VKTX) Completes Enrollment for Key Metaboli - GuruFocus
Viking Therapeutics completes enrollment in obesity drug maintenance study - Investing.com
4.73%
0.92%
자본화:
|
볼륨(24시간):